Pharmacological therapies in post stroke recovery: Recommendations for future clinical trials

Journal of Neurology

Volumn 261, Issue 8, 2014, Pages 1461-1468

  Chollet, F ^a   Cramer, S C ^b   Stinear, C ^c   Kappelle, L J ^d   Baron, J C ^e,f   Weiller, C ^g   Azouvi, P ^h   Hommel, M ⁱ   Sabatini, U ^j   Moulin, T ^k   Tardy, J ^l   Valenti, M ^m   Montgomery, S ⁿ   Adams, H ^o  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f INSERM   (France)

^g UNIVERSITY OF FREIBURG   (Germany)

^h LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

^l Clinique des Cedres   (France)

^m UNIVERSITY OF L'AQUILA   (Italy)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

^o UNIVERSITY OF IOWA   (United States)

more..

Author keywords

Brain plasticity; Clinical scales; Clinical trials; Outcome scales; Pharmacology; Statistical analysis; Stroke recovery

Indexed keywords

CITALOPRAM; FLUOXETINE; GROWTH FACTOR; MAPROTILINE; MONOCLONAL ANTIBODY; SEROTONIN UPTAKE INHIBITOR; NEUROPROTECTIVE AGENT;

BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONVALESCENCE; DEPRESSION; DISABILITY; HEMIPLEGIA; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; DRUG EFFECTS; PROCEDURES; STANDARDS; STROKE; TRENDS;

CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; RECOVERY OF FUNCTION; STROKE;

EID: 84906098359     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7172-z     Document Type: Review

References (40)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD et al (2013) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127(1):e6-e245
2. The national Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587
3. Kidwell CS, Liebeskind DS, Starkman S, Saver JL (2001) Trends in acute ischemic stroke trials through the 20th century. Stroke 32:1349-1359
4. Cramer SC (2008) Repairing the human brain after stroke. Ii. Restorative therapies. Ann Neurol 63:549-560
5. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C et al (2011) Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 10:123-130
6. Cramer SC, Stradling D, Brown DM, Carrillo-Nunez IM, Ciabarra A, Cummings M et al (2012) Organization of a United States county system for comprehensive acute stroke care. Stroke 43:1089-1093
7. Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397
8. Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17:796-808
9. Hermann DM, Chopp M (2012) Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 11:369-380
10. Wieloch T, Nikolich K (2006) Mechanisms of neural plasticity following brain injury. Curr Opin Neurobiol 16:258-264
11. Pekna M, Pekny M, Nilsson M (2012) Modulation of neural plasticity as a basis for stroke rehabilitation. Stroke 43:2819-2828
12. Baron JC, Cohen LG, Cramer SC, Dobkin BH, Johansen-Berg H, Loubinoux I et al (2004) Neuroimaging in stroke recovery: a position paper from the first International Workshop on neuroimaging and stroke recovery first International Workshop on neuroimaging and stroke recovery. Cerebrovasc Dis 18:260-267
13. Liepert J, Bauder H, Wolfgang HR, Miltner WH, Taub E, Weiller C (2000) Treatment-induced cortical reorganization after stroke in humans. Stroke 31:1210-1216
14. Chollet F, Albucher JF (2012) Strategies to augment recovery after stroke. Curr Treat Options Neurol 14:531-540
15. Liepert J (2008) Pharmacotherapy in restorative neurology. Curr Opin Neurol 21:639-643
16. Loubinoux I, Chollet F (2010) Neuropharmacology in stroke recovery. In: Cramer SC, Nudo RJ (eds) Brain repair after stroke. Cambridge University Press, Cambridge, pp 183-193
17. Chollet F, Acket B, Raposo N, Albucher JF, Loubinoux I, Pariente J (2013) Use of antidepressant medications to improve outcomes after stroke. Curr Neurol Neurosci Rep 13(1):318
18. Martinsson L, Hårdemark H, Eksborg S (2007) Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev 24(1):CD002090 (A comprehensive review on published and unpublished studies)
19. Zittel S, Weiller C, Liepert J (2008) Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 22:311-314
20. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M et al (1996) Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27:1211-1214
21. Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M et al (2011) Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry 19:1007-1015
22. Gopurappilly R, Pal R, Mamidi MK, Dey S, Bhonde R, Das AK (2011) Stem cells in stroke repair: current success & future prospects. CNS Neurol Disord: Drug Targets 10:741-756
23. Cramer SC (2010) Stratifying patients with stroke in trials that target brain repair. Stroke 41:S114-S116
24. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C et al (2012) Statistical analysis of the primary outcome in acute stroke trials. Stroke 43:1171-1178
25. Brinjikji W, Rabinstein AA, Cloft HJ (2012) Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than medicare payments. Stroke 43:1131-1133
26. Cramer SC, Koroshetz WJ, Finklestein SP (2007) The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents. Stroke 38:1393-1395
27. Nudo RJ (1999) Recovery after damage to motor cortical areas. Curr Opin Neurobiol 9:740-747
28. Murphy TH, Corbett D (2009) Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci 10:861-872
29. Stinear CM, Barber PA, Petoe M, Anwar S, Byblow WD (2012) The PREP algorithm predicts potential for upper limb recovery after stroke. Brain 135:2527-2535
30. Levy R, Benson R, Winstein C; for the Everest Study Investigators (2008) Cortical stimulation for upper-extremity hemiparesis from ischemic stroke: everest study primary endpoint results. In: International Stroke Conference, 2008
31. Pearson-Fuhrhop KM, Cramer SC (2010) Genetic influences on neural plasticity. PM R 2:S227-S240
32. Nouri S, Cramer SC (2011) Anatomy and physiology predict response to motor cortex stimulation after stroke. Neurology 77:1076-1083
33. Lindenberg R, Zhu LL, Ruber T, Schlaug G (2012) Predicting functional motor potential in chronic stroke patients using diffusion tensor imaging. Hum Brain Mapp 33:1040-1051
34. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N et al (2012) The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 43:86-91
35. Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-2758
36. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, European Stroke Organization Outcomes Working Group et al (2012) Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 43:1163-1170
37. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML et al (1998) Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke 29:2073-2075
38. Saver JL (2007) Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 38:3055-3062
39. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W (2004) Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis 18:124-129
40. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J, Optimising Analysis of Stroke Trials (OAST) Collaboration (2007) Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 38:1911-1915